Colin Walsh
CIK: 0001866174
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Attovia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (27 total)
- Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Indirect2M shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Conversion(C)Indirect478.5K shares- - Aug 6, 2026ATTO
Attovia Therapeutics, Inc.
Purchase(P)Indirect500K shares at avg. $17.00$8.5M - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect1.3K shares at avg. $22.03$29K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect200 shares at avg. $22.05$4K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect1.6K shares at avg. $22.06$34K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect3.4K shares at avg. $22.02$75K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect200 shares at avg. $22.10$4K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect480 shares at avg. $21.55$10K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect100 shares at avg. $22.11$2K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect753 shares at avg. $21.97$17K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect672 shares at avg. $22.02$15K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect7K shares at avg. $22.03$154K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Purchase(P)Indirect85K shares at avg. $21.00$1.8M - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect1.2K shares at avg. $21.84$26K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect1K shares at avg. $22.05$23K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect300 shares at avg. $20.84$6K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect443 shares at avg. $21.78$10K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect200 shares at avg. $22.05$4K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect700 shares at avg. $22.07$15K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect1.2K shares at avg. $22.19$26K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect100 shares at avg. $21.99$2K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect6.8K shares at avg. $21.61$146K - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect76.4K shares at avg. $21.04$1.6M - Aug 5, 2026ATTO
Attovia Therapeutics, Inc.
Sale(S)Indirect400 shares at avg. $22.02$9K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Conversion(C) | 1,957,134 | - | $0 | Indirect |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Conversion(C) | 478,498 | - | $0 | Indirect |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Purchase(P) | 500,000 | $17.00 | $8,500,000 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 1,332 | $22.03 | $29,344 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 200 | $22.05 | $4,410 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 1,556 | $22.06 | $34,325 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 3,402 | $22.02 | $74,912 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 200 | $22.10 | $4,420 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 480 | $21.55 | $10,344 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 100 | $22.11 | $2,211 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 753 | $21.97 | $16,543 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 672 | $22.02 | $14,797 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 6,970 | $22.03 | $153,549 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Purchase(P) | 85,000 | $21.00 | $1,785,000 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 1,180 | $21.84 | $25,771 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 1,040 | $22.05 | $22,932 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 300 | $20.84 | $6,252 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 443 | $21.78 | $9,649 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 200 | $22.05 | $4,410 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 700 | $22.07 | $15,449 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 1,163 | $22.19 | $25,807 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 100 | $21.99 | $2,199 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 6,763 | $21.61 | $146,148 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 76,418 | $21.04 | $1,607,835 | Indirect |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | Sale(S) | 400 | $22.02 | $8,808 | Indirect |
1-25 of 27 transactions
About WALSH COLIN
WALSH COLIN (SEC CIK 0001866174) files insider reports with the SEC as Director of Attovia Therapeutics, Inc. (ATTO).
Signal8 holds 3 ownership filings by WALSH COLIN (1 Form 3, 2 Form 4), filed between Aug 5, 2026 and Aug 28, 2026. Those filings report 27 transactions, from Aug 5, 2026 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WALSH COLIN's filings is in NEW YORK, NY.
Recent filings by WALSH COLIN
- Aug 6, 2026: Conversions of ATTO shares (2 lines, Form 4, code C).
- Aug 6, 2026: Open-market purchase of ATTO shares (Form 4, code P).
- Aug 5, 2026: Open-market sales of ATTO shares (10 lines, Form 4, code S).
- Aug 5, 2026: Open-market purchase of ATTO shares (Form 4, code P).
- Aug 5, 2026: Open-market sales of ATTO shares (11 lines, Form 4, code S).
Other insiders filing for Attovia Therapeutics, Inc. (ATTO)
- Fu Tao, President and CEO
- Chan Steven, Chief Financial Officer
- GOLDMAN SACHS GROUP INC, Officer
- Deep Track Biotechnology Master Fund, Ltd., 10% Owner
- venBio Global Strategic Fund IV, L.P., 10% Owner
- Redmile Group, LLC, 10% Owner